|Bid||167.37 x 100|
|Ask||167.44 x 300|
|Day's Range||166.52 - 168.43|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||15.91|
|Dividend & Yield||4.60 (2.68%)|
|1y Target Est||N/A|
With a slate of promising drugs hitting the market and in its development pipeline, Regeneron Pharmaceuticals is becoming one of biotechs most important players.
In 2Q17, Amgen’s (AMGN) Enbrel generated revenues of ~$1.5 billion, which represented a ~1% year-over-year decline and a ~24% quarter-over-quarter rise.
Amgen Inc NASDAQ/NGS:AMGN